What is ANVS's current stock price?

ANVS (Annovis Bio, Inc.) is currently trading at $2.23 with a market cap of $43.9M.

What sector is Annovis Bio, Inc. in?

Annovis Bio, Inc. (ANVS) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ANVS a good stock to buy?

Analysts have a Buy consensus on ANVS with a price target of $25.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ANVS Annovis Bio, Inc.

Healthcare

$2.23+3.72%ClosedMarket Cap: $43.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

19.87

P/S

0.00

EV/EBITDA

-0.72

DCF Value

$0.84

FCF Yield

-20580.6%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-318.1%

ROA

-251.9%

ROIC

-1199.7%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-17.6M	$—
Q4 null	$0.00	$-9.8M	$—
FY null	$0.00	$-28.9M	$—
Q3 null	$0.00	$-7.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$25.67

Target (Median)

$26.00

Target Range

$21.00 - $30.00

1 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Canaccord GenuityBuy

2026-04-14

Canaccord GenuityBuy

2025-09-30

HC Wainwright & Co.Buy

2025-09-03

HC Wainwright & Co.Buy

2025-06-09

Trading Activity

Insider Trades

View All

Hoffman Michael Bdirector

BuyThu May 21

Hoffman Michael Bdirector

BuyThu May 21

Hoffman Michael Bdirector

BuyThu May 21

Hoffman Michael Bdirector

BuyFri Apr 03

Hoffman Michael Bdirector

BuyMon Dec 08

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.26

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Peers